Pharmidex joins London Mayor Boris Johnson's trade mission to US
January 6, 2015

Boris Johnson is heading to the United States on a six-day trade mission aimed at bolstering London's science and technology industries.

Mr Boris Johnson’s US Trade Mission


Mr Boris Johnson, the Mayor of London has recently been in the US trying to attract investment for British businesses. Mr Johnson is using the US trade mission to promote London's TechCity - which supports the cluster of technology firms based in east London - and MedCity, which was launched last year to support life sciences.


He looked to visit Harvard University’s Stem Cell Institute (HSCI) in an attempt to bring together collaborations between London and Boston life sciences. Mr Johnson said “'The United States is a hugely important trading partner for London, offering massive opportunities for investment in this country and for businesses wanting to expand internationally. I want London to capitalise on the great relationships we have in Boston, New York City and Washington DC”.


In Boston and New York, the Mayor was joined by senior business figures from London's tech and life science sectors including Dr Mo Alavijeh of Pharmidex.


For more information please see: http://www.bbc.co.uk/news/uk-england-london-31161270

Thanks to our interns from City St George’s, University of London

June 19, 2026
A big thank you to our interns from City St George’s, University of London and heir fantastic contribution to Pharmidex over the past few months. They have supported scientific projects across the business, developed valuable technical skills and gained hands-on experience within a CRO environment. Their contribution has extended beyond the laboratory, helping with our website, marketing materials, conference preparation and business development activities. Science drives success, but communicating that science effectively is just as important. Our interns have helped us do both. Thank you for your hard work, enthusiasm, and dedication. We wish you every success in the next stage of your careers.

Pharmidex at the "Creative Disruption Forum: Modern Drug Discovery in Cambridge."

June 17, 2026
On 18 June, our COO, Ash Alavijeh , will join an industry panel discussing: "What are the advantages and disadvantages of working with UK-based Discovery CROs?" The session will explore the value of UK CROs in supporting innovation, protecting IP, accessing scientific expertise and accelerating drug discovery programmes. 📅 18 June 2025 📍 Cambridge 🕒 Panel Session: 12:20–12:45 We look forward to connecting with colleagues, collaborators, and innovators from across the life sciences community.

Congratulate Dr Mansoor Chishty as Director of DMPK at Pharmidex

June 16, 2026
This well-deserved appointment marks an important milestone in a remarkable career spanning more than 22 years at Pharmidex . Over the years, Dr Chishty has made a significant contribution to the growth of our DMPK capabilities, applying his extensive expertise in Drug Metabolism and Pharmacokinetics to support successful drug discovery and development programmes for clients worldwide. His scientific leadership, dedication and commitment to excellence have been instrumental in strengthening our services and supporting the continued success of Pharmidex . As we continue to grow and support innovative biopharmaceutical companies, we look forward to the impact Dr Chishty will make in this new role. Please join us in congratulating Dr Mansoor Chishty on this achievement and wishing him every success as Director of DMPK.
More Posts